Hoth Therapeutics, Inc. (HOTH) |
|
4.8 -0.12 (-2.44%)
|
01-27 16:00 |
|
Open: |
5 |
Pre. Close: |
4.92 |
|
High:
|
5.16 |
Low:
|
4.78 |
|
Volume:
|
116,536 |
Market Cap:
|
7(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:12 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 10.22  One year: 14.59 |
| Support: |
Support1: 2.7 Support2: 2.25 |
| Resistance: |
Resistance1: 8.75 Resistance2: 12.5 |
| Pivot: |
5.87  |
| Moving Average: |
MA(5): 5.01 MA(20): 6.28
MA(100): 6.23 MA(250): 10.02 |
| MACD: |
MACD(12,26): 0 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 2.9 %D(3): 3.4 |
| RSI: |
RSI(14): 44.8 |
| 52-week: |
High: 40.75 Low: 0.37 |
| Average Vol(K): |
3-Month: 767 (K) 10-Days: 68 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HOTH ] has closed above bottom band by 14.8%. Bollinger Bands are 2.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.17 - 5.2 |
5.2 - 5.23 |
|
Low:
|
4.7 - 4.73 |
4.73 - 4.77 |
|
Close:
|
4.74 - 4.8 |
4.8 - 4.85 |
|
Company Description |
|
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York. |
Headline News |
Wed, 25 Jan 2023
Hoth Therapeutics Picks Three Sites for Mid-Stage Trial in Skin Disorders in Cancer Patients - Marketscreener.com
Wed, 25 Jan 2023
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy - Yahoo Finance
Mon, 23 Jan 2023
How To Enjoy A Planet Hoth Winter In North Dakota & Minnesota - US 103.3
Mon, 23 Jan 2023
Lady Go-Hawks take first in Decorah, 5 girls finish 1st - Cedar Valley Daily Times
Fri, 20 Jan 2023
George Lucas Left A Lot Of Room For Interpretation When Writing ... - /Film
Tue, 17 Jan 2023
Doctor Aphra Once Saved the Rebels at Hoth - By Beating Darth ... - CBR - Comic Book Resources
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
1 (M) |
| Shares Float |
1 (M) |
|
% Held by Insiders
|
54.8 (%) |
|
% Held by Institutions
|
8.3 (%) |
|
Shares Short
|
22 (K) |
|
Shares Short P.Month
|
34 (K) |
Stock Financials |
|
EPS
|
-0.53 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.67 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-55 |
|
Return on Equity (ttm)
|
-103.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-11 (M) |
|
Levered Free Cash Flow
|
-7 (M) |
Stock Valuations |
|
PE Ratio
|
-9.06 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.71 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.59 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
